StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) stock

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.75+0.04 (+1.08%)

Close on Nov 17, 2026Market cap $286.12MP/E –Yield –

Fulcrum Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Fulcrum Therapeutics's price to sales ratio was 2.6× on Apr 30, 2025, against 157.4× a year earlier. Over the last 4 years it ranged from 1.9× to 229.8×, with a median of 32.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 20252.6×−0.5
2024Dec 31, 20243.1×−131.1
2023Dec 29, 2023134.3×+112.0
2022Dec 30, 202222.3×−16.8
2021Dec 31, 202139.1×–

More Fulcrum Therapeutics figures

See a number that looks wrong?